Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
QuintilesIMS
McKesson
Cipla
Argus Health
Merck
Accenture
UBS
Boehringer Ingelheim

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,642,268

« Back to Dashboard

Which drugs does patent 7,642,268 protect, and when does it expire?

Patent 7,642,268 protects SPIRIVA and is included in one NDA.

Protection for SPIRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-seven patent family members in thirty-six countries.
Summary for Patent: 7,642,268
Title:Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Abstract:The invention relates to a crystalline micronisate of (1 .alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl)o- xy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0.sup.2,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
Inventor(s): Bender; Helmut (Wiesbaden, DE), Graebner; Hagen (Ingelheim, DE), Schindler; Konrad (Ingelheim am Rhein, DE), Trunk; Michael (Ingelheim, DE), Walz; Michael (Bingen am Rhein, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Application Number:11/532,716
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Drugs Protected by US Patent 7,642,268

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,642,268

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 12 264Mar 20, 2002

Non-Orange Book US Patents Family Members for Patent 7,642,268

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,309,707 Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,642,268

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 100368410 ➤ Try a Free Trial
China 101220025 ➤ Try a Free Trial
Colombia 5611105 ➤ Try a Free Trial
Cyprus 1106923 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Chubb
McKinsey
Cipla
QuintilesIMS
Harvard Business School
US Department of Justice
Chinese Patent Office
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.